• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Insilico Medicine founder and CEO Alex Zhavoronkov, Ph.D., presents on AI Drug Discovery for NIH National Institute on Drug Abuse

Bioengineer by Bioengineer
May 23, 2023
in Health
Reading Time: 2 mins read
0
Alex Zhavoronkov, PhD, Presents NIH NIDA Talk
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven drug discovery company, will present a virtual talk on Artificial Intelligence for Drug Discovery, Biomarker Development and Generation of Novel Chemistry on May 25, 10-11am ET as part of the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) Advanced Courses in New Product Development. 

Alex Zhavoronkov, PhD, Presents NIH NIDA Talk

Credit: NIDA

Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven drug discovery company, will present a virtual talk on Artificial Intelligence for Drug Discovery, Biomarker Development and Generation of Novel Chemistry on May 25, 10-11am ET as part of the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) Advanced Courses in New Product Development. 

Zhavoronkov is an expert in generative biology and chemistry as well as in aging and longevity research, and is one of the cofounders of the Aging Research and Drug Discovery conference, now in its 10th year. 

The Company’s end-to-end Pharma.AI platform includes target identification (PandaOmics), drug design (Chemistry42), and clinical trial outcome prediction (InClinico) and has produced two drugs that have reached clinical trials. Insilico’s lead drug for the devastating chronic lung disease idiopathic pulmonary fibrosis (IPF), the first AI-discovered and AI-designed drug to advance to clinical trials, will soon be entering Phase 2 trials with patients. And Insilico’s generative AI-designed drug for COVID-19 and related variants has been approved for clinical trials and has a number of design advantages over existing COVID-19 drugs. 

There are 31 drugs in Insilico’s pipeline available for partnering and licensing for indications including cancer, fibrosis, and central nervous system diseases, and the Company has nominated 12 preclinical candidates in the past two years, most recently a potentially best-in-class preclinical candidate targeting ENPP1 for cancer immunotherapy and the potential treatment of Hypophosphatasia (HPP).

Insilico has partnered with leading pharma companies, including Fosun Pharma and Sanofi, to accelerate their programs. 
 

About Insilico Medicine

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, connects biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases, and aging-related diseases.

For more information, visit www.insilico.com 



Share13Tweet8Share2ShareShareShare2

Related Posts

The RESTART Trial Explores Drug Targeting Toxic HIV Protein

October 2, 2025

Student Nurses’ Realities During Practical Exams in Ghana

October 2, 2025

Quantum Nanodiamond Test Boosts Early COVID Detection

October 2, 2025

Parkinson’s Tremors Revealed by Long-Term STN-DBS

October 2, 2025

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    91 shares
    Share 36 Tweet 23
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    76 shares
    Share 30 Tweet 19
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    64 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Early EBV-DNA Clearance Boosts Nasopharyngeal Survival

The RESTART Trial Explores Drug Targeting Toxic HIV Protein

Decoding the Magnetic Mathematics of Breast Health

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.